VRX - Valeant Pharmaceuticals Intern
This page shows which of the focused investors we track hold VRX and how their positions changed, so you can see how much conviction the group has in the stock.
In Q1 2016 it was held by 10 managers with an aggregate reported value of $2.16B, which is 0.30% of the combined portfolio.
As of Q1 2016, 10 tracked institutional managers held VRX (Valeant Pharmaceuticals Intern) with an aggregate reported value of $2.16B — 0.30% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades VRX — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q1 2016
- Ticker
- VRX
13F data is delayed and excludes shorts/non-13F assets.
Long holders
| 1 | Ruane Cunniff LP - Ruane Cunniff LP | 6.19% | Reduce -14.3% | 30,308,449 | $797.11M |
| 2 | Bill Ackman - Pershing Square Capital Management | 6.41% | Add +30.1% | 21,591,122 | $567.85M |
| 3 | ValueAct Capital - ValueAct Capital | 3.94% | - | 14,994,261 | $394.35M |
| 4 | Christopher Davis - Davis Advisors | 0.84% | Add +91.3% | 7,240,337 | $190.42M |
| 5 | Glenn Greenberg - Brave Warrior Advisors | 2.61% | Reduce -67.5% | 2,034,281 | $53.5M |
| 6 | Bill Miller - Miller Value Partners | 2.06% | New | 1,580,950 | $41.58M |
| 7 | First Eagle - First Eagle Investment Management | 0.10% | Reduce -8.8% | 1,495,332 | $39.33M |
| 8 | Francis Chou - Chou Associates | 8.35% | New | 976,843 | $25.73M |
| 9 | David Tepper - Appaloosa Management | 0.50% | New | 945,000 | $24.85M |
Put holders — short bets
1 manager has put options on VRX — a right to sell at strike. The reported value is the underlying market value (notional), not the option premium paid.
| 1 | First Eagle - First Eagle Investment Management | Add +378.8% | 11,970 | $22.11M |